CagriSema and semaglutide · 68 weeks
REDEFINE 1
CagriSema (cagrilintide 2.4 mg plus semaglutide 2.4 mg, once weekly) reduced weight by 20.4% at 68 weeks, compared with 3.0% on placebo.
Randomized controlled trial
REDEFINE 2: CagriSema in type 2 diabetes with obesity
In people with type 2 diabetes, CagriSema reduced weight by 13.7% at 68 weeks, compared with 3.4% on placebo; the estimated difference was −10.4 percentage points (95% CI, −11.2 to −9.5; p < 0.001).
Davies MJ et al. Cagrilintide–Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes. New England Journal of Medicine, 2025. DOI: 10.1056/NEJMoa2502082
- Prepared by
- Alex Gonzalez
- Last updated
- Sources
- 2 sources
No clinical review. No advertising from drug companies and no affiliate links.How we work
Key facts
- Drug
- CagriSema
- Design
- Randomized controlled trial
- Participants
- 1,206
- Duration
- 68 weeks
- Funding
- Novo Nordisk
- Registry
- NCT05394519
- Population
- 1,206 adults with obesity or overweight and type 2 diabetes.
- Primary outcome
- Percentage change in body weight and proportion losing at least 5% at 68 weeks, CagriSema versus placebo.
What it found
- CagriSema 2.4/2.4 mg weekly−13.7%
- Placebo−3.4%
Difference: −10.4 points vs placebo (95% CI, −11.2 to −9.5).
Figures from the paperSee the results in a chart
In people with type 2 diabetes, CagriSema reduced weight by 13.7% at 68 weeks, compared with 3.4% on placebo; the estimated difference was −10.4 percentage points (95% CI, −11.2 to −9.5; p < 0.001). Of those treated, 73.5% reached an HbA1c of 6.5% or less, compared with 15.9% on placebo. As in other trials, weight loss was smaller than in people without diabetes.
Limitations
Funded by Novo Nordisk. No active comparator (it was not compared with semaglutide alone). The product was not approved in any country as of the review date.
What it means for you
In people with type 2 diabetes and obesity or overweight, CagriSema reduced weight by an average of 13.7% over 68 weeks, less than in people without diabetes. It is an investigational combination. These data help show where research is heading; they are not a basis for choosing a treatment today.
Further reading
Sources
The original paper and the records consulted for this summary, with the date they were accessed.
- New England Journal of Medicine.Davies MJ, et al. Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes. N Engl J Med. 2025;393(7):648-659.accessed .
- National Library of Medicine (PubMed).PubMed record PMID 40544432 (abstract).accessed .